BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Pardes Goes from Stealth to SPAC in Less than Two Years with COVID-19 Pill

  The COVID-19 pandemic has led to faster R&D, faster approvals, faster science than ever before. It’s even leading to faster company development.

  June 30, 2021

   · 

  2 min read

   · 

  Kate Goodwin
• 

  BioMidwest

  Research Roundup: Big Focus on Alzheimer’s Disease and More

  Every week there are numerous scientific studies published. This week there was an unusual number of research stories revolving around Alzheimer’s disease. Here’s a look at some of the more interesting ones.

  June 30, 2021

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  Alpine and Merck Study Checkpoint, Anti-PD-1 Cancer Combo in Collab Study

  Alpine Immune Sciences has entered into a collaboration agreement with Merck to evaluate the efficacy and safety of Alpine’s checkpoint in combination with Merk’s anti-PD-1 therapy in cancer.

  June 30, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  Global Roundup: Astellas and FibroGen Receive Positive CHMP Opinion for CKD Drug

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

  June 30, 2021

   · 

  10 min read

   · 

  Alex Keown
• 

  Business

  California Biotech Aditum Bio Launches New Spinout Company for Treatment-Resistant Depression

  The new portfolio firm, Ancora Bio, is focused on developing a new drug to address treatment-resistant depression.

  June 30, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Deals

  Intellia Tops Busy Period with $600 Million Public Offering

  Cambridge, Mass.-based Intellia Therapeutics has had a busy week, but they’re topping it off with the announcement of their public offering price of $145 per share for 4,137,931 shares.

  June 30, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  How the U.S. Military Primed Windtree CEO Craig Fraser for C-Suite Success

  Craig Fraser, CEO of Windtree Therapeutics, became a U.S. Marine at age 17, learning to perform and lead under pressure in the field before eventually leading in the C-suite.

  June 30, 2021

   · 

  6 min read

   · 

  Gail Dutton
• 

  Business

  QIAGEN Partners with Verogen to Bolster Forensics Field

  The two companies will collaborate to market Verogen’s forensically validated NGS workflows alongside QIAGEN’s full range of forensic-grade chemistries and sample prep automation.

  June 30, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Female-Founded Antheia Raises $73 Million to Support Synthetic Biology for Essential Medicines

  Christina Smolke said the financing will enable the company to use its synthetic biology platform to support essential medications that rely on plant-based materials.

  June 30, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  FUJIFILM Diosynth to Expand Manufacturing Capabilities With $850 Million Infusion

  The cash infusion will support the growth of its manufacturing capabilities in the US and the UK and the demands for gene therapies, antibodies, and vaccines such as COVID-19.

  June 30, 2021

   · 

  2 min read

   · 

  Alex Keown